CEO SUMMARY: Many of the recently issued reimbursement rates for molecular diagnostic tests are inadequate and in fact are lower than the cost of running the tests, lab experts say. Smaller laboratories that specialize in developing and selling molecular tests could be forced to close. As many as 20 or more molecular labs operate in […]
Low 2013 Molecular Rates May Bankrupt Some Labs
Prices for some high-volume molecular test fails to cover the lab’s cost to perform these tests
- By R. Lewis Dark
- > From the Volume XX No. 2 February 11, 2013 Issue
- Tags: acla, apf, ASCP, billing and coding, cap, clfs, clinical lab, clinical lab fee schedule, clinical laboratories, Clinical Laboratory, clinical laboratory industry, clinical laboratory test, clinical laboratory tests, cpt, cpt code, Diagnostic tests, diagnostics lab, donna beasley, FDA regulations, genetic test, genetic testing, genetic tests, hie, impac, lab industry, lab test, lab testing, laboratories, laboratory association, laboratory coding, laboratory companies, laboratory industry, laboratory test, laboratory tests, mckesson revenue, mckesson revenue management solutions, medical lab, medical laboratories, Medical laboratory, medical laboratory test, medical laboratory tests, Medicare, Medicare Part B, MolDx, molecular diagnostic, molecular diagnostic test, molecular diagnostic tests, molecular diagnostics lab, molecular lab, molecular testing, molecular tests, mopath, pathologists, personalized medicine, revenue cycle, revenue cycle management, revenue cycle management services, revenue management, specialty lab, test menu, the clinical laboratory, the laboratory, xifin
